NewsRelease
TwoResearch Articles Cite HemogloBind™ To Reduce AnalyticalInterferences
MONMOUTHJUNCTION, NJ, November27, 2018 --Biotech Support Group reports on two research articles describing thedescribing the simplicity and efficiency of their hemoglobindepletion technology for improving analyte measurements from red celllysates and liver perfusion fluids. The citations are:
O’Connell,Grant C., et al. "Monocyte-lymphocytecross-communication via soluble CD163 directly links innate immunesystem activation and adaptive immune system suppression followingischemic stroke."Scientificreports7.1 (2017): 12940, and
Laing,Richard W., et al. "Theuse of an acellular oxygen carrier in a human liver model ofnormothermic machine perfusion."Transplantation101.11 (2017): 2746.
Inthe first reference, the purpose of this study was to investigateCD163 as a possible effector of stroke-induced adaptive immune systemsuppression as this is a scavenger receptor expressed on innateimmune cell populations. A soluble peptide with lympho-inhibitoryproperties can be shed from the plasma membrane via themetalloprotease ADAM17. The article states “Totalhemocyte fractions were thawed, mixed with NP-40 lysis buffer (ThermoFisher) at a 1 to 1 ratio, and depleted of hemoglobin via theHemogloBind hemoglobin removal kit (Biotech Support Group, MonmouthJunction, NJ)… ADAM17 activity was measured in 200 ug of totalhemocyte lysate”. The authors provide novelevidence that the innate immune system employs protective mechanismsaimed at mitigating the risk of post-stroke autoimmune complications,and that CD163 is a key mediator of this phenomenon.
Inthe second reference, the authors present the first experience ofusing an acellular hemoglobin-based oxygen carrier (HBOC) Hemopure ina human model of Normothermic machine perfusion of the liver (NMP-L).This is a novel technique that preserves liver grafts undernear-physiological conditions while maintaining their normalmetabolic activity. The article states “All perfusates underwenthaemoglobin depletion using Hemoglobind (BioTech Support Group LLC,Monmouth Junction, NJ) as per the manufacturer’s instructions,except using a 1:8 ratio to ensure removal of all free haemoglobin.Perfusate levels of 8-OH-dG were quantified using a competitive ELISA(Abcam) as per the manufacturers protocol” .The authors conclusionis that Hemopure can be used as an alternative oxygen carrier topacked red cells in NMP-L perfusion fluid.
“Thelarge amount of hemoglobin in samples of this type presents a specialchallenge for quantitative analysis. These articles demonstrate yetagain that HemogloBind™ can reduce the interference associated withlarge concentrations of hemoglobin, without compromising the recoveryand analysis of the protein(s) of interest.” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Clickhere for more information on HemogloBind™
Clickhere for more information on all of our Hemoglobin Removal products
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc
732-274-2866
[email protected]